Vasculitis & polymyalgia rheumatica
Real-world efficacy and safety of avacopan in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis: a retrospective comparative study
Authors' conclusion
In a real-world practice, avacopan was effective with an acceptable safety profile, enabling steroid sparing, improved renal recovery and reduced relapse rates, including in patients receiving combined induction therapy.
Study context
- Population
- Patients with new-onset or relapsing AAV
- Participants
- 35 vs 70
- Exposure
- Avacopan plus standard induction therapy vs matched controls receiving standard therapy
- Avacopann = 35
- Controlsn = 70reference
- Outcome
- Remission (Birmingham Vasculitis Activity Score (BVAS)=0, prednisolone ≤5 mg/day)
- Follow-up
- 6 and 12 months
Methodological detailssingle-centre, matched controls
- Single-centre
- Matched controls
Main finding
As reported in the abstract
Remission · 6 months
Observational data: associations, not effects.
Secondary outcomes
Relapse · including after treatment discontinuation
P = 0.003
Time to GC tapering ≤5 mg/day
P < 0.001
Cumulative GC dose
P = 0.008
| Outcome | Avacopan | Controls | P value |
|---|---|---|---|
| Remission (co-primary) · 12 monthsTended to be higher with avacopan | 86% | — not stated in the abstract | P = 0.11 |
| Change in eGFR · 1 year | +18 mL/min | +7 mL/min |
— not stated in the abstract
Safety
- Avacopan discontinuation due to adverse events
- 26% · 9 of 35
Original publication
Real-world efficacy and safety of avacopan in ANCA-associated vasculitis: a retrospective comparative study. RMD Open. Published 15 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →